公开(公告)号：US20230087410A1

公开(公告)日：2023-03-23

申请号：US17735258

申请日：2022-05-03

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Brian C. Shook ,  In Jong Kim ,  Thomas P. Blaisdell ,  Jianming Yu ,  Joseph D. Panarese ,  Yat Sun Or

IPC: C07D513/04 ,  A61K45/06 ,  C07D495/04 ,  A61K31/56 ,  C07D498/08 ,  C07D413/14 ,  C07D413/12 ,  A61K31/58 ,  C07D243/16 ,  C07D471/08 ,  C07D491/048 ,  A61K31/5513 ,  C07D417/14

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20230084932A1

公开(公告)日：2023-03-16

申请号：US17727993

申请日：2022-04-25

Applicant: MAA Laboratories, Inc.

Inventor： Anjani Kumar Jha

IPC: A61K9/51 ,  A61K31/196 ,  A61K31/4535 ,  A61K31/58 ,  B02C15/00

Abstract: This invention relates to methods of preparing nanotherapeutic compounds and compositions comprising nanotherapeutic compounds. The nanotherapeutic compounds prepared according to the methods provided herein are useful for the treatment of disease, for example, cancer, in a subject in need thereof.

公开(公告)号：US20230049350A1

公开(公告)日：2023-02-16

申请号：US17874621

申请日：2022-07-27

Applicant: Purdue Pharmaceutical Products L.P.

Inventor： Thomas Jorg Mehrling ,  Claudio Festuccia

IPC: A61K31/4184 ,  A61K38/06 ,  A61K31/407 ,  A61K31/427 ,  A61K31/5377 ,  A61K31/573 ,  A61K31/58 ,  A61K31/69 ,  A61K38/05 ,  A61K31/502 ,  A61K31/55 ,  A61K39/395 ,  A61K45/06

Abstract: There is provided a compound of formula I or a pharmacologically acceptable salt thereof: for use in the treatment of a brain cancer selected from a MGMT positive astrocytic brain tumour, a metastatic brain cancer and primary CNS lymphoma and a method of treating said brain cancers in a patient in need thereof comprising administering to the patient said compound of formula I or a pharmacologically acceptable salt thereof.

公开(公告)号：US20230046317A1

公开(公告)日：2023-02-16

申请号：US17794323

申请日：2021-01-21

Applicant: Emory University

Inventor： Keqiang Ye

IPC: A61K31/427 ,  A61P35/00 ,  A61K31/506 ,  A61K31/58 ,  A61K31/519 ,  A61K31/337 ,  A61K31/704 ,  A61K31/4985 ,  A61K38/17 ,  A61K31/4745 ,  A61K31/5377 ,  A61K31/198

Abstract: This disclosure relates to compounds that inhibit glutathione S-transferases (GSTs) and/or NAD(P)H:quinone oxidore-ductase 1 (NQO1) for uses in treating cancer. In certain embodiments, this disclosure relates to compositions and uses of N-(thia-zol-2-yl)-carboxamide derivatives such as a N-(5-nitrothiazol-2-yl)-carboxamide derivatives for treating cancer such as glioblastoma. In certain embodiments, this disclosure relates to pharmaceutical compositions comprising a N-(thiazol-2-yl)-carboxamide derivative such as a N-(5-nitrothiazol-2-yl)-carboxamide derivative which is a compound of formula (I), or derivative, prodrug or salt thereof and a pharmaceutically acceptable excipient, wherein X, R1, R2, and R3 substituents are reported herein.

公开(公告)号：US20230040879A1

公开(公告)日：2023-02-09

申请号：US17893384

申请日：2022-08-23

Applicant: Seed Health, Inc.

Inventor： Joseph E. Kovarik

IPC: A61K35/74 ,  A61K31/715 ,  A61K31/58 ,  A61K38/17

Abstract: Various embodiments of the present invention are directed to the field of treating and preventing osteoporosis, with particular embodiments directed to a method of ameliorating, treating, or preventing osteoporosis in a human subject employing tomatidine, xylitol, rapamycin, etc., as well as modifying an individuals microbiome to reduce the likelihood of osteoporosis.

公开(公告)号：US11559507B2

公开(公告)日：2023-01-24

申请号：US16575168

申请日：2019-09-18

Applicant: MEXICHEM FLUOR S.A. DE C.V.

Inventor： Stuart Corr ,  Timothy James Noakes

IPC: A61K31/167 ,  A61K9/00 ,  A61K31/58 ,  A61K31/573 ,  A61K31/56

Abstract: A pharmaceutical composition is described. The composition comprises: (i) at least one formoterol compound selected from formoterol, pharmaceutically acceptable salts of formoterol, prodrugs of formoterol, solvates of formoterol, solvates of pharmaceutically acceptable salts of formoterol and solvates of prodrugs of formoterol; (ii) at least one corticosteroid; (iii) a surfactant component comprising at least one surfactant compound; and (iv) a propellant component comprising 1,1-difluoroethane (R-152a).

公开(公告)号：US11559506B2

公开(公告)日：2023-01-24

申请号：US16575069

申请日：2019-09-18

Applicant: MEXICHEM FLUOR S.A. DE C.V.

Inventor： Stuart Corr ,  Timothy James Noakes

IPC: A61K31/167 ,  A61K9/00 ,  A61K31/58 ,  A61K31/573 ,  A61K31/56

Abstract: A pharmaceutical composition is described. The composition comprises: (i) at least one formoterol compound selected from formoterol, pharmaceutically acceptable salts of formoterol, prodrugs of formoterol, solvates of formoterol, solvates of pharmaceutically acceptable salts of formoterol and solvates of prodrugs of formoterol; (ii) at least one corticosteroid; (iii) a surfactant component comprising at least one surfactant compound; and (iv) a propellant component comprising 1,1-difluoroethane (R-152a).

公开(公告)号：US11541053B2

公开(公告)日：2023-01-03

申请号：US17826922

申请日：2022-05-27

Applicant: Aneira Pharma, Inc.

Inventor： John Edward Wurst

IPC: A61K31/506 ,  A61P17/14 ,  A61K31/222 ,  A61K31/25 ,  A61K31/5575 ,  A61K31/58 ,  A61K47/10 ,  A61K47/12 ,  A61K47/26 ,  A61K38/13 ,  A61K9/00

Abstract: Compositions and methods for the treatment of hair growth and the prevention of hair loss.

公开(公告)号：US20220370370A1

公开(公告)日：2022-11-24

申请号：US17879362

申请日：2022-08-02

Applicant: ASTRAZENECA AB

Inventor： LENNART LINDFORS ,  TOMAS KJELLMAN

IPC: A61K9/51 ,  A61K45/06 ,  A61K9/127 ,  C12N15/88 ,  A61K9/107 ,  A61K31/58 ,  A61K31/7088

Abstract: Disclosed herein are lipid nanoparticles comprising a lipid phase and at least one lipophilic anti-inflammatory agent, and pharmaceutical compositions comprising lipid nanoparticles and methods for using lipid nanoparticles.

公开(公告)号：US20220362264A1

公开(公告)日：2022-11-17

申请号：US17437144

申请日：2020-03-17

Applicant: DISPERSOL TECHNOLOGIES, LLC. ,  BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Dave MILLER ,  Urvi GALA ,  Robert O. WILLIAMS, III ,  Angela SPANGENBERG

IPC: A61K31/58 ,  A61K9/20

Abstract: The present disclosure relates to pharmaceutical formulations including abiraterone and a cyclic oligomer, as well as tablets including such pharmaceutical formulations, methods of forming such pharmaceutical formulations, and methods of administering such pharmaceutical formulations or tablets.